Swing Therapeutics, Inc.
Mike Rosenbluth is the CEO of Swing Therapeutics, Inc., a company focused on developing digital treatments for autoimmune conditions and chronic pain. Prior to their current role, they served as Vice President, Strategy and Business Development at Veracyte, Inc. from 2016 to 2019, and held the position of Vice President of Pulmonology from 2014 to 2016. Mike also worked as an Investment Professional at Versant Ventures from 2012 to 2014. Before transitioning to the healthcare industry, Mike worked as an Engagement Manager at McKinsey & Company from 2008 to 2012. Mike began their career as a Graduate Student Researcher at UC Berkeley, conducting research in the field of bioengineering under the supervision of Dr. Dan Fletcher from 2002 to 2008.
Mike Rosenbluth received their Bachelor's and Master's degrees in Mechanical Engineering from Stanford University, where they studied from 1996 to 2002. Later, they pursued further education at the University of California, Berkeley, where they obtained a PhD in Bioengineering from 2002 to 2008.
This person is not in any teams
Swing Therapeutics, Inc.
Swing is creating the next generation of safe and effective digital therapeutics for people with chronic conditions. Our team of passionate scientists, clinicians, and technologists are partnering with some of the world’s top researchers to develop evidence-based transformative digital treatments. Swing’s solutions empower patients to regaincontrol of their illnesses. Together, we are helping people achieve improved health so that they can lead more joyful, vibrant lives.